药物相关不良反应可能预测阿帕替尼治疗晚期肝细胞癌的疗效。
Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma.
机构信息
Department of Hepatobiliary Surgery, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.
Department of Gynecologic Oncology, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.
出版信息
BMC Gastroenterol. 2022 Oct 31;22(1):441. doi: 10.1186/s12876-022-02542-0.
BACKGROUND
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths worldwide every year, and most HCC patients are diagnosed with advanced disease and can only receive systemic treatment. TKIs are the most important components of the systemic treatment of HCC and have both good efficacy and adverse events (AEs). METHODS: This analysis included 207 patients with locally advanced unresectable or metastatic HCC who received oral treatment with apatinib. We analyzed the overall survival (OS) and progression-free survival (PFS) of patients with or without corresponding AEs to evaluate which AEs can predict the efficacy of apatinib.
RESULTS
Patients with hand-foot syndrome (HFS; p = 0.005), proteinuria (p = 0.006) and diarrhea (p < 0.001) had significantly better OS than those without corresponding AEs, and the appearance of HFS (p = 0.006) and proteinuria (p = 0.004) was associated with longer PFS.
CONCLUSION
Among all the AEs induced by apatinib in the treatment of advanced HCC, proteinuria could potentially predict PFS, and diarrhea was a potential predictor of OS.
背景
肝细胞癌（HCC）是全球每年癌症相关死亡的第四大主要原因，大多数 HCC 患者被诊断为晚期疾病，只能接受系统治疗。TKI 是 HCC 系统治疗的最重要组成部分，具有良好的疗效和不良反应（AE）。方法：本分析纳入了 207 例接受阿帕替尼口服治疗的局部晚期不可切除或转移性 HCC 患者。我们分析了有或无相应 AE 的患者的总生存期（OS）和无进展生存期（PFS），以评估哪些 AE 可以预测阿帕替尼的疗效。结果：手足综合征（HFS；p=0.005）、蛋白尿（p=0.006）和腹泻（p<0.001）患者的 OS 明显优于无相应 AE 的患者，HFS（p=0.006）和蛋白尿（p=0.004）的出现与更长的 PFS 相关。结论：在阿帕替尼治疗晚期 HCC 引起的所有 AE 中，蛋白尿可能是 PFS 的潜在预测因素，而腹泻是 OS 的潜在预测因素。
Zotero 插件